Commitments and Contingencies (Details) |
1 Months Ended | 3 Months Ended | 6 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Aug. 18, 2024
USD ($)
shares
|
Apr. 24, 2024
USD ($)
|
Jan. 17, 2024
USD ($)
|
Mar. 15, 2023
USD ($)
|
Sep. 08, 2022
USD ($)
|
Apr. 01, 2018
USD ($)
|
Jun. 30, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Mar. 31, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Dec. 31, 2024
USD ($)
|
|
| Commitments and Contingencies [Line Items] | ||||||||||||||
| License fees and milestone payments, description | More specifically, the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of a New Drug Application by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense itself. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income. | |||||||||||||
| Royalty expenses | $ 10,000 | $ 10,000 | $ 20,000 | $ 20,000 | ||||||||||
| Percentage of grant funding | 5.00% | |||||||||||||
| Grant funding received amount | $ 1,000,000 | |||||||||||||
| Percentage of amount to be paid in cash | 50.00% | |||||||||||||
| Percentage of amount to be paid in stock | 50.00% | |||||||||||||
| Annual fee | $ 430,000 | 375,000 | ||||||||||||
| Recognized compensation expense | 124,099 | $ 202,378 | 360,830 | 428,368 | ||||||||||
| Total separation agreement cost | 3,127,187 | $ 411,091 | ||||||||||||
| Compensation to be paid | $ 22,000 | |||||||||||||
| Consulting Agreement [Member] | ||||||||||||||
| Commitments and Contingencies [Line Items] | ||||||||||||||
| Recognized compensation expense | $ 75,120 | $ 73,620 | ||||||||||||
| Related Party [Member] | ||||||||||||||
| Commitments and Contingencies [Line Items] | ||||||||||||||
| Accrued expenses | $ 20,000 | 20,000 | ||||||||||||
| Dr. Johnson [Member] | ||||||||||||||
| Commitments and Contingencies [Line Items] | ||||||||||||||
| Percentage of grant funding | 10.00% | |||||||||||||
| Grant funding received amount | $ 1,000,000 | |||||||||||||
| Grant funding amount | ||||||||||||||
| Separation payments | $ 56,792 | |||||||||||||
| Payment due | $ 40,000 | |||||||||||||
| Stock-based compensation, common stock issued for services (in Shares) | shares | 2,400 | |||||||||||||
| Total separation agreement cost | $ 0.98 | |||||||||||||
| Dr. Johnson [Member] | Consulting Agreement [Member] | ||||||||||||||
| Commitments and Contingencies [Line Items] | ||||||||||||||
| Total separation agreement cost | $ 2,352 | |||||||||||||
| Dr. Johnson [Member] | Consulting Agreement [Member] | ||||||||||||||
| Commitments and Contingencies [Line Items] | ||||||||||||||
| Recognized compensation expense | $ 108,700 | |||||||||||||
| Board of Director [Member] | ||||||||||||||
| Commitments and Contingencies [Line Items] | ||||||||||||||
| Number of director | 1 | |||||||||||||
| Chief Operating Officer [Member] | ||||||||||||||
| Commitments and Contingencies [Line Items] | ||||||||||||||
| Recognized compensation expense | $ 25,000 | |||||||||||||